Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDS Biotechnology CorpPDSB · Entity 7939 | Director · President/CEO | January 12, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDS Biotechnology Corp
Report date January 12, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-01-12 | Direct | 548,782 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 548,782 · Balance 548,782 F1: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Mar 3, 2026 23:47 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 548,782 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001140361-26-007649 · form4.xml · derivative · entry 1 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 548,782 Underlying: Common Stock · 548,782 shares Expires 2036-01-12 F1 · derivative.exercise_date: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 12, 2025 Filed Jul 25, 2025 22:12 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001140361-25-027405 · form4.xml · derivative · entry 2 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-06-12 F2 · derivative.exercise_date: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on June 12, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| February 28, 2024 Filed Jul 25, 2025 22:12 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $5.87 | $0.00 |
DisclosureSEC source: 0001140361-25-027405 · form4.xml · derivative · entry 1 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on February 28,2025, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:59 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 385,300 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001140361-23-000824 · form4.xml · derivative · entry 1 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,300 Underlying: Common Stock · 385,300 shares Expires 2033-01-05 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 385,300 shares of Common Stock, will become exercisable on January 5, 2024, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 5, 2027. Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 21:47 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 219,535 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001140361-22-044259 · form4.xml · derivative · entry 3 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 219,535 shares Expires 2022-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This stock option was fully vested in accordance with its terms. Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 21:47 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | Tax withholdingCommon Stock | 175,184 | $9.78 | $1,713,299.52 |
DisclosureSEC source: 0001140361-22-044259 · form4.xml · nonDerivative · entry 2 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,866 F2 · kind: On December 2, 2022, Dr. Bedu-Addo made a net exercise of 219,535 stock options, resulting in his acquisition of 44,351 common shares of the Issuer. Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 21:47 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | Exercise / conversionCommon Stock | 219,535 | $6.57 | $1,442,344.95 |
DisclosureSEC source: 0001140361-22-044259 · form4.xml · nonDerivative · entry 1 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On December 2, 2022, Dr. Bedu-Addo made a net exercise of 219,535 stock options, resulting in his acquisition of 44,351 common shares of the Issuer. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 21:05 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 291,500 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001140361-22-002188 · form4.xml · derivative · entry 1 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,500 Underlying: Common Stock · 291,500 shares Expires 2032-01-19 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 291,500 shares of Common Stock, will become exercisable on January 19, 2023, with 25% vesting on that date and the remaining vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 19, 2026. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:26 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 53,174 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001140361-21-021503 · form4.xml · derivative · entry 3 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,174 shares Expires 2021-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Stock Option is fully vested in accordance with its terms. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:26 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | Tax withholdingCommon Stock | 27,166 | $12.86 | $349,354.76 |
DisclosureSEC source: 0001140361-21-021503 · form4.xml · nonDerivative · entry 2 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,515 F1 · kind: On June 15, 2021, Mr. Bedu-Addo made a net exercise of 53,174 stock options, resulting in his acquisition of 26,008 common shares of the Issuer. The transaction was made pursuant to an exception to a lock-up agreement between Mr. Bedu Addo and Cantor Fitzgerald & Co.in connection with a public offering of common shares by the Issuer which closed on June 17, 2021. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:26 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | Exercise / conversionCommon Stock | 53,174 | $6.57 | $349,353.18 |
DisclosureSEC source: 0001140361-21-021503 · form4.xml · nonDerivative · entry 1 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 673,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On June 15, 2021, Mr. Bedu-Addo made a net exercise of 53,174 stock options, resulting in his acquisition of 26,008 common shares of the Issuer. The transaction was made pursuant to an exception to a lock-up agreement between Mr. Bedu Addo and Cantor Fitzgerald & Co.in connection with a public offering of common shares by the Issuer which closed on June 17, 2021. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 21:10 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 707,800 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001140361-20-027860 · form4.xml · derivative · entry 1 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,800 Underlying: Common Stock · 707,800 shares Expires 2030-12-08 F1 · derivative.exercise_date: The option was granted on December 8, 2020, subject to stockholder approval of the Issuer's Second Amended and Restated 2014 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c). The option is not exercisable until stockholder approval has been obtained. Contingent upon stockholder approval, one-quarter of the shares subject to the option shall vest on December 8, 2021, and the remainder shall vest in equal monthly installments thereafter until fully vested on December 8, 2024. In the event stockholder approval is not obtained pursuant to the terms of grant, then the Reporting Person shall surrender the option to the Company for cancellation. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:24 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-20-014759 · form4.xml · derivative · entry 1 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 125,000 shares of Common Stock, will become exercisable on June 23, 2021, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:33 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0001127602-19-023219 · form4.xml · derivative · entry 1 BEDU-ADDO FRANK · CIK 0001770756 · Director · President/CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-06-28 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 100,000 shares of Common Stock, will become exercisable on June 28, 2020, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.